A phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicenter study of DU-176b in patients with non-valvular atrial fibrillation (NVAF) aged 80 years or older who are ineligible for available oral anticoagulation therapy
Latest Information Update: 19 Feb 2024
At a glance
- Drugs Edoxaban (Primary)
- Indications Embolism and thrombosis; Stroke
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms ELDERCARE-AF
- Sponsors Daiichi Sankyo Company
- 13 Nov 2023 Results of Sub-Analysis assessing efficacy and safety of low-dose edoxaban according to body weight in very elderly patients with atrial fibrillation presented at the American Heart Association Scientific Sessions 2023
- 11 May 2022 Results of a subanalysis assessed the prognostic outcomes of very elderly non-valvular atrial fibrillation (NVAF) patients ineligible for standard anticoagulation treatment would vary according to B-type natriuretic peptide stratification published in the American Heart Journal
- 15 Nov 2021 Results of subanalysis assessing effects of edoxaban in extremely elderly patients (aged > 90 Years) presented at the American Heart Association Scientific Sessions 2021